Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$5.88 USD
-0.61 (-9.34%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $5.87 -0.01 (-0.09%) 6:40 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 1 - 20 ( 366 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Financial Results Reported; Reiterate Neutral; Adjusting PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Innovation Passport Designation Awarded in UK; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results Reported; Reiterate Neutral; Instituting $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2023 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-3112 Head and Neck Cancer Collaboration Inked; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-3107 BLA Submission Expected in 2H24; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Genomic Medicine Deep Dive-Redrawing Frontiers at the Coding Level
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-3107 Granted Accelerated Approval Pathway; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-3107 Obtains Breakthrough Therapy Designation; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-3107 Receives Orphan Drug Designation in EU; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Opinion on Orphan Drug Designation For INO-3107 in EU; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1b Data For Ebola Booster Vaccine Presented; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
REVEAL2 Results Mixed; 2022 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
More Positive Results from Recurrent Respiratory Papillomatosis Trial; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Interim Results in Recurrent Respiratory Papillomatosis; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R